JULY 2022LIFE SCIENCES REVIEW9well as a number of health agencies' safety monitoring databases. This allows Avanir to apply statistical methodology, in addition to Individual Case Safety Report (ICSR) review, for "signal detection" which helps develop more accurate and complete assessments of the product safety profile.Shared TechnologiesI can't leave out mentioning the abundance of shared technologies across our global network. Avanir also has access to Otsuka's innovative technologies and safety intelligence tools. These technologies and tools include automated data reconciliation, automated aggregate report generation, literature screening, advanced safety data analytical solutions, state-of-the-art data mining algorithms and statistical techniques for detecting, analyzing and managing safety signals. Shared Experience While the availability of databases and analytical tools helps develop more efficient pharmacovigilance functionality for both clinical investigations and post-market commercialization, collective medical judgment must always be the core driver of decision making when it comes to safety. Being part of a global pharmaceutical family also grants Avanir access to the wealth of experience our sister companies have to offer. Companies like Otsuka U.S. are able to offer both their pharmacovigilance expertise, as well as their global intelligence. At Avanir, we're also proud to bring our own central nervous system experience and expertise to Otsuka. Sometimes we learn and sometimes we teach, but together we grow and learn from our shared experiences.Drug Safety Remains Number One Pharmacovigilance is essential both to bringing a safe drug to market and for maintaining an effective safety compliance program. As a small pharmaceutical company working within a larger global pharmaceutical organization, Avanir is able to operate under one harmonized pharmacovigilance system by sharing resources and experience, all in the focus on our number one priority­drug safety. Pharmacovigilance is essential both to bringing a safe drug to market and for maintaining an effective safety compliance program
< Page 8 | Page 10 >